Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025)

Candel Therapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at $32.9 million for Q4 2025.

• In Q4 2025, Net Cash Flow fell 61.77% year-over-year to $32.9 million; the TTM figure through Dec 2025 stood at $17.2 million (down 74.38% YoY), while the FY2025 annual figure was $17.2 million, down 74.38% from the prior year.
• Net Cash Flow came in at $32.9 million for Q4 2025 at Candel Therapeutics, up from -$13.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $86.1 million in Q4 2024 to a low of -$13.7 million in Q3 2025.
• A 5-year average of $4.2 million and a median of -$6.4 million in 2021 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 2964.06% in 2021 and plunged 192.37% in 2023, its largest moves.
• Candel Therapeutics' Net Cash Flow stood at -$5.7 million in 2021, then fell by 24.09% to -$7.1 million in 2022, then slipped by 6.25% to -$7.6 million in 2023, then jumped by 1237.33% to $86.1 million in 2024, then sank by 61.77% to $32.9 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered $32.9 million, -$13.7 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison